AAAAAA

   
Results: 1-7 |
Results: 7
Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer
Authors: Birner, P Oberhuber, G Stani, J Reithofer, C Samonigg, H Hausmaninger, H Kubista, E Kwasny, W Kandioler-Eckersberger, D Gnant, M Jakesz, R
Citation: P. Birner et al., Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer, CLIN CANC R, 7(6), 2001, pp. 1669-1675
Prognostic relevance of three histological grading methods in breast cancer
Authors: Latinovic, L Heinze, G Birner, P Samonigg, H Hausmaninger, H Kubista, E Kwasny, W Gnant, M Jakesz, R Oberhuber, G
Citation: L. Latinovic et al., Prognostic relevance of three histological grading methods in breast cancer, INT J ONCOL, 19(6), 2001, pp. 1271-1277
Interferon gamma in the first-line therapy of ovarian cancer: a randomizedphase III trial
Authors: Windbichler, GH Hausmaninger, H Stummvoll, W Graf, AH Kainz, C Lahodny, J Denison, U Muller-Holzner, E Marth, C
Citation: Gh. Windbichler et al., Interferon gamma in the first-line therapy of ovarian cancer: a randomizedphase III trial, BR J CANC, 82(6), 2000, pp. 1138-1144
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: Final resultsof a randomised phase III study
Authors: Hausmaninger, H Moser, R Samonigg, H Mlineritsch, B Schmidt, H Pecherstorfer, M Fridrik, M Kopf, C Nitsche, D Kaider, A Ludwig, H
Citation: H. Hausmaninger et al., Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: Final resultsof a randomised phase III study, EUR J CANC, 35(3), 1999, pp. 380-385
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
Authors: Kucera, E Speiser, P Gnant, M Szabo, L Samonigg, H Hausmaninger, H Mittlbock, M Fridrik, M Seifert, M Kubista, E Reiner, A Zeillinger, R Jakesz, R
Citation: E. Kucera et al., Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients, EUR J CANC, 35(3), 1999, pp. 398-405
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
Authors: Jakesz, R Hausmaninger, H Haider, K Kubista, E Samonigg, H Gnant, M Manfreda, D Tschurtschenthaler, G Kolb, R Stierer, M Fridrik, M Mlineritsch, B Steindorfer, P Mittlbock, M Steger, G
Citation: R. Jakesz et al., Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer, J CL ONCOL, 17(6), 1999, pp. 1701-1709
Trials of the Austrian Breast Cancer Group (ABC)
Authors: Jakesz, R Hausmaninger, H Samonigg, H Kubista, E Haider, K Mlineritsch, B Schmid, M Tausch, C Reiner, G Renner, K Stierer, M Jatzko, G Hofbauer, F Fridrik, M Schennach, W Sevelda, P Dadak, C Haid, A Scholz, R Lenzhofer, P Steindorfer, P Berger, A Mischinger, HJ
Citation: R. Jakesz et al., Trials of the Austrian Breast Cancer Group (ABC), ZBL CHIR, 123, 1998, pp. 28-32
Risultati: 1-7 |